| Company Name: | Arena Pharmaceuticals Inc | | | Ticker Symbol: | ARNA | | CIK Number: | 0001080709 | | WWW Address: | http://www.arenapharm.com |
| CEO: | Mr. Amit D. Munshi | | No. of Employees: | 106 |
| Common Issue Type: | CS | | Business Description: | Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors to address major therapeutic areas like cardiovascular & metabolic diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 16.1317 |  0.9017 | 16.11 | 16.14 | 15.37 | 16.17 | 14.92 | 307230 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 512.1 | 31.7 | 0.00 | -0.90 | 0.00 | 0.0 | 0.0 | 17.75 - 1.13 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 15.23 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 512.1 | mil |
| Latest Shares Outstanding | 31.7 | mil |
| Earnings pS (EPS) | -0.90 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 1,169,575 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 24.7 | mil |
| Float as % of Shares Outstanding | 1.0 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.50 | % |
| Gross Profit Margin | 87.6 | % |
| EBITDA Margin | -5.7 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 58.2 | % |
| Return on Assets (ROA) | -10.6 | % |
| Return on Equity (ROE) | -48.2 | % |
| Return on Capital Invested (ROCI) | -14.4 | % |
| Current Ratio | 1.9 | |
| Leverage Ratio (Assets/Equity) | 4.2 | |
| Interest Cover | -2.5 | |
| Total Debt/Equity (Gearing Ratio) | 1.64 | |
| LT Debt/Total Capital | 61.0 | % |
| Working Capital pS | 1.76 | $ |
| Cash pS | 0.00 | $ |
| Book-Value pS | 0.84 | $ |
| Tangible Book-Value pS | 1.18 | $ |
| Cash Flow pS | -2.50 | $ |
| Free Cash Flow pS | -2.53 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 17.76 | |
| Price/Tangible Book Ratio | 0.00 | |
| Price/Cash Flow | -6.0 | |
| Price/Free Cash Flow | -5.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -4.3 | -4 | 1,335,218 | 1,326,582 |
| 4 Weeks | 17.75 | 1.22 | 1.32 | 1042.4 | 1042 | 1,387,006 | 29,127,136 |
| 13 Weeks | 17.75 | 1.13 | 1.46 | 932.9 | 930 | 2,010,234 | 128,654,978 |
| 26 Weeks | 17.75 | 1.13 | 1.53 | 885.6 | 879 | 1,809,853 | 228,041,495 |
| 52 Weeks | 17.75 | 1.13 | 1.70 | 787.1 | 768 | 1,635,899 | 412,246,635 |
| YTD | 17.75 | 1.13 | - | 929.4 | 922 | 1,825,872 | 222,756,500 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 15.59 | 11.16 | 3.28 | 2.09 | 1.97 | 0.00 | 0.00 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.58 | 0.9 | 0.15 |
| Income | | 0.0 | |
| Dividend | | 0.0 | |
| Capital Spending | | NA | |
| R&D | -22.62 | NA | -18.37 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 8.4 | 8.4 | 116.9 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.09 | 0.09 | 0.35 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 33.14 |
| Current Ratio | 1.9 |
| Quick Ratio (Acid Test) | 1.7 |
| Liquidity Ratio (Cash) | 2.84 |
| Receivables Turnover | 9.9 |
| Average Collection Period | 36 |
| Working Capital/Equity | 140.4 |
| Working Capital pS | 0.23 |
| Cash-Flow pS | -0.26 |
| Free Cash-Flow pS | -0.26 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.79 |
| Financial Leverage Ratio (Assets/Equity) | 1.6 |
| Debt Ratio | 38.6 |
| Total Debt/Equity (Gearing Ratio) | 1.64 |
| LT Debt/Equity | 1.55 |
| LT Debt/Capital Invested | 163.5 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | -2.5 |
| Interest/Capital Invested | 6.19 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.00 |
| Tobin's Q Ratio | 2.79 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -59.76 |
| Enterprise Value (EV)/Free Cash Flow | -6.58 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 0.00 |
| Price/Book Ratio - LTM | 17.76 |
| Price/Cash Flow Ratio | -6.0 |
| Price/Free Cash Flow Ratio - LTM | -5.9 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | -150.0 |
| 5-Y Low P/E Ratio | -12.6 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.29 |
| Tangible Book Value pS - LTM | 1.18 |
| Book Value pS - LTM | 0.84 |
| Capital Invested pS | 1.26 |
| Cash pS - LTM | 0.00 |
| Cash Flow pS - LTM | -2.50 |
| Free Cash Flow pS - LTM | -2.53 |
| Earnings pS (EPS) | -0.90 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -50.89 |
| Free Cash Flow Margin 5YEAR AVG | -144.37 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | -1.6 |
| Equity Productivity | 3.11 |
| Return on Equity (ROE) | -0.5 |
| Return on Equity (ROE) - 5YEAR AVRG. | -1.1 |
| Capital Invested Productivity | 3.11 |
| Return on Capital Invested (ROCI) | -0.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -0.4 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | -0.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | -0.2 |
| Gross Profit Margin | 87.6 |
| Gross Profit Margin - 5YEAR AVRG. | 0.8 |
| EBITDA Margin - LTM | -5.7 |
| EBIT Margin - LTM | -13.2 |
| Pre-Tax Profit Margin | -1.6 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -1.6 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 545,758 |
| Revenue per Employee | 1,169,575 |
| Net Income per Employee | |
| Average Collection Period | 545,758 |
| Receivables Turnover | 9.9 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 1.9 |
| Inventory/Sales | 5.4 |
| Accounts Payble/Sales | 4.82 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 2.21 |
| Fixed Assets Turnover | 2.52 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 1.37 |
| Revenue per $ Plant | 2.83 |
| Revenue per $ Common Equity | 3.11 |
| Revenue per $ Capital Invested | 3.11 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 25.2 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 1.0 |
| Research & Devlopment (R&D) as % of Revenue | 53.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 53.6 |
|
|  
| | |  |  | | |
